中国防痨杂志2024，Vol.46Issue(3)：260-266,7.DOI:10.19982/j.issn.1000-6621.20230450
世界卫生组织《结核分枝杆菌耐药相关基因突变目录(第2版)》解读
Interpretation of the World Health Organization's Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance(2nd Edition)
摘要
Abstract
Drug-resistant tuberculosis is a major obstacle to the achievement of the End TB Strategy by 2035.The World Health Organization(WHO)promotes the use of rapid molecular drug susceptibility testing technology for early diagnosis of drug-resistant tuberculosis.Covering comprehensive and reliable drug resistance-related mutations is the key to improving the reliability of molecular drug resistance diagnosis.WHO has released the second edition of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance in November 2023.This catalogue described more comprehensive and accurate drug-resistance-related gene mutations based on the largest collection of multinational Mycobacterium tuberculosis complex isolates,so as to support the development and improvement of the molecular drug susceptibility testing technology.This article provides a detailed interpretation of the updates in the analysis process and drug-resistant mutations in the second edition of the catalogue compared with the first edition,and looks forward to the future direction of improving the catalogue.关键词
分枝杆菌,结核/抗药性,细菌/微生物敏感性试验/基因/突变Key words
Mycobacterium tuberculosis/Drug resistance,bacterial/Microbial sensitivity tests/Genes/Mutation分类
医药卫生引用本文复制引用
裴少君,欧喜超..世界卫生组织《结核分枝杆菌耐药相关基因突变目录(第2版)》解读[J].中国防痨杂志,2024,46(3):260-266,7.基金项目
国家重点研发计划(2022YFC2305204)National Key Research and Development Program(2022YFC2305204) （2022YFC2305204）
